Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
View Patent ↗Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.
1. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a homogeneous population of cells obtained from human umbilical cord tissue in an amount effective to treat the disease or damage, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate; does not produce CD31, CD34, CD117 or HLA-DR; and expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of interleukin 8 and reticulon 1.
2. The method of claim 1 , wherein the population of cells expresses oxidized low density lipoprotein receptor 1 , reticulon, chemokine receptor ligand 3, or granulocyte chemotactic protein 2.
3. The method of claim 1 , wherein the population of cells expresses CD10, CD13, CD44, CD73, and CD90.
4. The method of claim 1 , wherein the population of cells is administered by injection or infusion.
5. The method of claim 1 , wherein the population of cells is administered encapsulated within an implantable device.
6. The method of claim 1 , wherein the population of cells is administered by implantation of a matrix comprising the population of cells.
7. The method of claim 1 , wherein the population of cells is administered with at least one other cell type.
8. The method of claim 7 , wherein the at least one other cell type is administered simultaneously with, or before, or after, the population of cells obtained from human umbilical cord tissue.
9. The method of claim 1 , wherein the population of cells is administered with at least one agent.
10. The method of claim 9 , wherein the at least one agent is administered simultaneously with, before, or after administration of the population of cells obtained from human umbilical cord tissue.
11. The method of claim 1 , wherein the population of cells exert a trophic effect on the kidney of the patient.
12. The method of claim 1 , wherein the damage to the kidney is induced by age, trauma, toxin exposure, drug exposure, radiation exposure, oxidation, immune-complex deposition, or transplant rejection.
13. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a composition comprising a soluble cell fraction prepared from a homogeneous population of cells obtained from human umbilical cord tissue, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate; does not produce CD31, CD34, CD117 or HLA-DR; and expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell increased levels of interleukin 8 and reticulon 1.
14. A method of treating a patient having a disease of or damage to at least one kidney, comprising administering to the patient a composition comprising a homogeneous population of cells obtained from human umbilical cord tissue and a lysate, extracellular matrix, or conditioned medium prepared from said homogeneous population of cells obtained from human umbilical cord tissue, wherein the umbilical cord tissue is substantially free of blood, and wherein the population of cells is capable of self-renewal and expansion in culture and has the potential to differentiate; does not produce CD31, CD34, CD117 or HLA-DR; and expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell increased levels of interleukin 8 and reticulon 1.